December 11, 2014 8:06 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
In a report published Thursday, Credit Suisse analyst Jason Kantor downgraded the rating on
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
(NASDAQ: ARIA) from Neutral to Underperform, and lowered the price target from $8.00 to $6.00.In the report, Credit Suisse noted, “We believe that Iclusig will likely remain the last option for CML patients who have specific resistant mutations or fail other therapies. Near-term US sales will benefit from the implementation of the new pricing strategy that doubled the 30 mg price. However, we think this will likely be short-lived and sales will face a drop in H2:15 when ARIA moves to true flat pricing. We are downgrading to Underperform and reducing our TP to $6 from $8. Model changes increase our 2015 EPS estimates and decrease our 2016 EPS estimate.”Ariad Pharmaceuticals closed on Wednesday at $7.02.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.